Clinical Trials

23 results for Bladder Cancer


A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer

  • Condition: Infiltrating Bladder Urothelial Carcinoma
  • Intervention: Other: Radiation + cisplatin, Other: Radiation + cisplatin + gemcitabine
  • Study ID: NCT01495676
View Trial

Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: Pembrolizumab, Drug: Cisplatin, Radiation: Radiotherapy
  • Study ID: NCT02662062
View Trial

Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging

  • Condition: Muscle-invasive Bladder Cancer
  • Intervention: Other: Whole-body FDG PET-CT
  • Study ID: NCT02462239
View Trial

Phase I Study of Hypofractionated Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) in the Treatment of Advanced Bladder Cancer

  • Condition: Invasive Bladder Cancer
  • Intervention: Drug: Pembrolizumab, Radiation: Radiotherapy
  • Study ID: NCT02560636
View Trial

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)

  • Condition: Cholangiocarcinoma, Gall Bladder Carcinoma
  • Intervention: Drug: Gemcitabine, Drug: Cisplatin, Other: Observation
  • Study ID: NCT02170090
View Trial

Prospective Randomized Trial of Adjuvant Radiotherapy Following Surgery and Chemotherapy in Muscle Invasive Transitional Cell Carcinoma of Urinary Bladder

  • Condition: Bladder Cancer, Urothelial Carcinoma Bladder
  • Intervention: Radiation: Adjuvant RT
  • Study ID: NCT02951325
View Trial

A Phase II Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects With Non-metastatic Transitional Cell Carcinoma of the Bladder

  • Condition: Carcinoma, Transitional Cell
  • Intervention: Drug: MPDL3280A Dose Level 1, Drug: MPDL3280A Dose Level 2, Drug: MPDL3280A Dose Level 3
  • Study ID: NCT02451423
View Trial

Lymphadenectomy in Urothelial Carcinoma in the Renal Pelvis and Ureter

  • Condition: Ureteral Neoplasms [C12.758.820.875]
  • Intervention: Procedure: Lymphadenectomy in conjugation with nephroureterectomy, Procedure: Nephroureterectomy without lymphadenectomy
  • Study ID: NCT02607709
View Trial

A Phase II Open Label Single Arm Study of Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)

  • Condition: Bladder Cancer
  • Intervention: Drug: Nivolumab
  • Study ID: NCT03171025
View Trial

Randomized Phase II Study of Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder

  • Condition: Urothelial Carcinoma, Bladder Cancer
  • Intervention: Drug: Nivolumab in combination with Urelumab, Drug: Nivolumab monotherapy
  • Study ID: NCT02845323
View Trial

A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicinium (Oportuzumab Monatox, VB4-845) in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With BCG

  • Condition: Urinary Bladder Neoplasms
  • Intervention: Drug: Durvalumab, Drug: Vicinium
  • Study ID: NCT03258593
View Trial

A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ)

  • Condition: Bladder Cancer
  • Intervention: Drug: Nivolumab, Drug: Ipilimumab, Procedure: Radical cystectomy
  • Study ID: NCT03520491
View Trial

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)

  • Condition: Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
  • Intervention: Drug: Atezolizumab, Drug: Cisplatin, Drug: Fluorouracil, Drug: Gemcitabine, Drug: Mitomycin, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Other: Survey Administration
  • Study ID: NCT03775265
View Trial

Pilot Study of Celecoxib Combined With Gemcitabine and Cisplatin for Neoadjuvant Treatment of Localized, Muscle-Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: Celecoxib, Drug: Gemcitabine, Drug: Cisplatin
  • Study ID: NCT02885974
View Trial

A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle-

  • Condition: Bladder Cancer, Muscle-Invasive Bladder Cancer, BMS-986205
  • Intervention: Biological: Nivolumab, Drug: BMS-986205, Drug: Gemcitabine, Drug: Cisplatin, Drug: BMS-986205 Placebo
  • Study ID: NCT03661320
View Trial

A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Mus

  • Condition: Muscle Invasive Bladder Cancer
  • Intervention: Drug: Durvalumab, Drug: Cisplatin, Drug: Gemcitabine
  • Study ID: NCT03732677
View Trial

A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-

  • Condition: Urinary Bladder Cancer, Muscle-invasive
  • Intervention: Drug: Pembrolizumab, Drug: Gemcitabine, Drug: Cisplatin, Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Drug: Placebo
  • Study ID: NCT03924856
View Trial

A Phase 1b-2 Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

  • Condition: Urinary Bladder Cancer, Invasive Bladder Cancer
  • Intervention: Combination Product: nivolumab 480mg, Combination Product: nivolumab 3mg/kg, ipilimumab 1mg/kg, Combination Product: nivolumab 1mg/kg, ipilimumab 3mg/kg
  • Study ID: NCT03844256
View Trial

A Pilot Study of 18Fluorine-Fluciclovine Positron Emission Tomography/Computed Tomography for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

  • Condition: Bladder Cancer, Urothelial Carcinoma
  • Intervention: Drug: 18F-fluciclovine, Device: PET/CT
  • Study ID: NCT04018053
View Trial

A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: Durvalumab
  • Study ID: NCT03768570
View Trial

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEY

  • Condition: Urinary Bladder Neoplasms
  • Intervention: Drug: Pembrolizumab, Radiation: Conventional Radiotherapy (Bladder only), Radiation: Conventional Radiotherapy (Bladder and pelvic nodes), Radiation: Hypofractionated Radiotherapy (Bladder only), Drug: Cisplatin, Drug: Fluorouracil (5-FU), Drug: Mitomycin C (MMC), Drug: Gemcitabine, Drug: Placebo to Pembrolizumab
  • Study ID: NCT04241185
View Trial

Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)

  • Condition: Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
  • Intervention: Drug: Infigratinib, Drug: Placebo
  • Study ID: NCT04197986
View Trial

A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)

  • Condition: Muscle Invasive Bladder Cancer
  • Study ID: NCT04700124
View Trial